Predict your next investment

HEALTHCARE | Biotechnology
epidisease.co

See what CB Insights has to offer

Founded Year

2014

Stage

Grant | Alive

Total Raised

$400K

Last Raised

$400K | 3 yrs ago

About EpiDisease

EpiDisease is a provider of biomedical solutions, epigenetic diagnostic tools, and characterization of new epigenetic drugs, thus encouraging translational research and improving the health and welfare of people.

EpiDisease Headquarter Location

C/Catedràtic Agustín Escardino, 9

Paterna, 46980,

Spain

+34 960 420 157

Latest EpiDisease News

Fundación Botín to Invest €844K in Spanish Biotech Startups Innitius, EpiDisease - Novobrief

Mar 26, 2020

Fundación Botín to invest €844K in Spanish biotech startups Innitius, EpiDisease 2 years ago Through its Mind the Gap entrepreneurship program,  Fundación Botín will invest €844,000 in two Spanish biotech startups, Innitius and EpiDisease. In the case of Innitius , the investment will be made in two years, and the amount will amount to €500,000, while EpiDisease will have a financing of €344,000, EFE Emprende reported on Wednesday . Created in 2011, the Mind the Gap program promotes biotechnological entrepreneurship to enable startups with commercial potential, developed by Spanish scientific institutions, to reach the market to generate social and economic development. Its objective is to cover the gap that separates science from business and society. To this end, the Mind the Gap entrepreneurship program selects business projects based on technology from the area of ​​life sciences generated in Spanish research institutions, to which it provides: Financial investment, up to a maximum of €500,000 per project, for a maximum period of two years. Accompanying the project, through a specific methodology to support maturation, which includes the incorporation into the project of an expert advisor appointed by the Botín Foundation, who will provide guidance and support in those critical aspects to convert projects arising in the academic field in viable business initiatives. Innitius and EpiDisease will join the other five companies that are part of the “Mind the Gap” program, focused on entrepreneurship in the life sciences of the Fundación Botín. Innitius develops and offers reliable in-vivo technologies which anticipate early enough the pathologies diagnostic through the use of torsional waves principle. The Spanish biotech startup is a Spinoff of University of Granada (UGr) and Andalusian Public Health System (SAS), and it was born as a result of several common research projects which have given finally the Fine Birth device. At present it is working on the Fine Birth development, with the main objective of changing the gynecology and obstetrics praxis through the improvement of delivery associated events diagnosis. This technology uses torsion ultrasound for the diagnosis of pathologies associated with childbirth, with special emphasis on premature birth and induction of labor. The importance of this area lies in the fact that premature birth is the leading cause of infant mortality in developed countries and the second in those in the process of development. With this technology, the company aims to double the success rate of gynecologists detecting premature birth, which is currently at 30%, thus enabling better preparation for this. The mission of Valencia-based EpiDisease is to provide its customers with biomedical solutions, epigenetic diagnostic tools, and characterization of new epigenetic drugs, thus encouraging translational research and improving the health and welfare of people. EpiDisease is developing a molecular test that would be performed with a device called Scolipro, a test that will diagnose idiopathic scoliosis in adolescents with high specificity to be able to decide in a personalized way the treatment of patients. In addition, this device will reduce the use of X-rays, the current detection method of the disease, and with it the risk of cancer, since only a blood sample will be necessary. This disease begins as a slight deformation of about 10 degrees in adolescence, however it can get worse up to 40 degrees (which would make it a serious scoliosis) in the following years and affects 36 million patients in the world, one million in Europe.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EpiDisease

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EpiDisease is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.